Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

医学 儿科 疾病负担 疾病负担 病毒 呼吸道疾病 疾病 2019年冠状病毒病(COVID-19) 呼吸系统 重症监护医学 内科学 病毒学 传染病(医学专业) 肺
作者
You Li,Xin Wang,Dianna M. Blau,Mauricio T. Caballero,Daniel R. Feikin,Christopher John Gill,Shabir Ahmed Madhi,Saad B. Omer,Eric A. F. Simões,Harry J. Campbell,Ana Bermejo Pariente,Darmaa Bardach,Quique Bassat,Jean‐Sébastien Casalegno,Giorgi Chakhunashvili,Nigel W. Crawford,Daria Danilenko,Lien Anh Ha Do,Marcela Echavarría,Angela S. de Gentile
出处
期刊:The Lancet [Elsevier BV]
卷期号:399 (10340): 2047-2064 被引量:2189
标识
DOI:10.1016/s0140-6736(22)00478-0
摘要

Background Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0–60 months, resulting in a total of 118 200 deaths worldwide. Since then, several community surveillance studies have been done to obtain a more precise estimation of RSV associated community deaths. We aimed to update RSV-associated acute lower respiratory infection morbidity and mortality at global, regional, and national levels in children aged 0–60 months for 2019, with focus on overall mortality and narrower infant age groups that are targeted by RSV prophylactics in development. Methods In this systematic analysis, we expanded our global RSV disease burden dataset by obtaining new data from an updated search for papers published between Jan 1, 2017, and Dec 31, 2020, from MEDLINE, Embase, Global Health, CINAHL, Web of Science, LILACS, OpenGrey, CNKI, Wanfang, and ChongqingVIP. We also included unpublished data from RSV GEN collaborators. Eligible studies reported data for children aged 0–60 months with RSV as primary infection with acute lower respiratory infection in community settings, or acute lower respiratory infection necessitating hospital admission; reported data for at least 12 consecutive months, except for in-hospital case fatality ratio (CFR) or for where RSV seasonality is well-defined; and reported incidence rate, hospital admission rate, RSV positive proportion in acute lower respiratory infection hospital admission, or in-hospital CFR. Studies were excluded if case definition was not clearly defined or not consistently applied, RSV infection was not laboratory confirmed or based on serology alone, or if the report included fewer than 50 cases of acute lower respiratory infection. We applied a generalised linear mixed-effects model (GLMM) to estimate RSV-associated acute lower respiratory infection incidence, hospital admission, and in-hospital mortality both globally and regionally (by country development status and by World Bank Income Classification) in 2019. We estimated country-level RSV-associated acute lower respiratory infection incidence through a risk-factor based model. We developed new models (through GLMM) that incorporated the latest RSV community mortality data for estimating overall RSV mortality. This review was registered in PROSPERO (CRD42021252400). Findings In addition to 317 studies included in our previous review, we identified and included 113 new eligible studies and unpublished data from 51 studies, for a total of 481 studies. We estimated that globally in 2019, there were 33·0 million RSV-associated acute lower respiratory infection episodes (uncertainty range [UR] 25·4–44·6 million), 3·6 million RSV-associated acute lower respiratory infection hospital admissions (2·9–4·6 million), 26 300 RSV-associated acute lower respiratory infection in-hospital deaths (15 100–49 100), and 101 400 RSV-attributable overall deaths (84 500–125 200) in children aged 0–60 months. In infants aged 0–6 months, we estimated that there were 6·6 million RSV-associated acute lower respiratory infection episodes (4·6–9·7 million), 1·4 million RSV-associated acute lower respiratory infection hospital admissions (1·0–2·0 million), 13 300 RSV-associated acute lower respiratory infection in-hospital deaths (6800–28 100), and 45 700 RSV-attributable overall deaths (38 400–55 900). 2·0% of deaths in children aged 0–60 months (UR 1·6–2·4) and 3·6% of deaths in children aged 28 days to 6 months (3·0–4·4) were attributable to RSV. More than 95% of RSV-associated acute lower respiratory infection episodes and more than 97% of RSV-attributable deaths across all age bands were in low-income and middle-income countries (LMICs). Interpretation RSV contributes substantially to morbidity and mortality burden globally in children aged 0–60 months, especially during the first 6 months of life and in LMICs. We highlight the striking overall mortality burden of RSV disease worldwide, with one in every 50 deaths in children aged 0–60 months and one in every 28 deaths in children aged 28 days to 6 months attributable to RSV. For every RSV-associated acute lower respiratory infection in-hospital death, we estimate approximately three more deaths attributable to RSV in the community. RSV passive immunisation programmes targeting protection during the first 6 months of life could have a substantial effect on reducing RSV disease burden, although more data are needed to understand the implications of the potential age-shifts in peak RSV burden to older age when these are implemented. Funding EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
精明邑发布了新的文献求助10
刚刚
Beyond完成签到 ,获得积分10
刚刚
wheat的应助被11111采纳,获得10
刚刚
很好的完成签到 ,获得积分10
刚刚
摩尔庄园种菜高手完成签到,获得积分10
刚刚
hujieshi完成签到,获得积分10
刚刚
刚刚
脂蛋白抗原完成签到,获得积分10
刚刚
keyanrubbish完成签到,获得积分10
1秒前
stop here发布了新的文献求助10
1秒前
Ayan完成签到,获得积分10
1秒前
科研小糊涂完成签到,获得积分10
1秒前
HaohaoLi完成签到,获得积分10
1秒前
ying完成签到,获得积分10
1秒前
HIy完成签到,获得积分10
1秒前
鲤鱼鑫磊发布了新的文献求助10
1秒前
Lyy完成签到 ,获得积分10
1秒前
Jsl完成签到,获得积分10
1秒前
ZC完成签到,获得积分10
1秒前
1秒前
搞怪鞅完成签到,获得积分10
2秒前
2秒前
魅域苍穹完成签到,获得积分10
2秒前
dde发布了新的文献求助10
2秒前
zaq66996完成签到,获得积分10
2秒前
2秒前
DiJia完成签到 ,获得积分10
2秒前
大力哈密瓜完成签到,获得积分10
2秒前
龙龙龙完成签到,获得积分10
3秒前
abbb完成签到,获得积分10
3秒前
天天完成签到 ,获得积分10
3秒前
frederick完成签到,获得积分10
3秒前
3秒前
筱梦完成签到,获得积分10
3秒前
木火灰完成签到,获得积分10
4秒前
嘻嘻发布了新的文献求助10
4秒前
简单冬亦西完成签到,获得积分10
4秒前
tttt完成签到 ,获得积分10
4秒前
清脆山槐完成签到,获得积分10
5秒前
秋天的雪完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152226
求助须知:如何正确求助?哪些是违规求助? 9549007
关于积分的说明 21689901
捐赠科研通 7740494
什么是DOI,文献DOI怎么找? 3425145
关于科研通互助平台的介绍 2550358
邀请新用户注册赠送积分活动 2468652